Statistics from Altmetric.com
- Hepatocellular Carcinoma
- Reverse Transcription Polymerase Chain Reaction
- Clinicopathological Parameter
- Cancer Immunotherapy
- Testis Antigen
Many therapies such as surgery, chemical or physical approaches have been used for treatment of HCC; however, the outcome is still poor. Cancer immunotherapy is considered to be one of the promising strategies in recent years.
Expression of CTAs genes including MAGE A3, MAGE A4, MAGE C2 and NY-ESO-1 genes was detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 71 HCC patients.
87.3% of HCC tumor tissue samples expressed at least 1 CTAs. HCC adjacent non-cancerous tissues did not express CTAs. 78.9% tumor tissue samples expressed MAGE-A3 mRNA, 33.8% samples expressed MAGE-A4 mRNA, 74.6% samples expressed MAGE-C2 mRNA and 14.1% samples expressed NY-ESO-1 mRNA. The expression of CTAs showed correlation with Ki67(r=0.27, P=0.02) and tumor stages (r=0.31, P=0.01), no correlation with clinical parameters such as age, gender, ALT, HLA-A2 positive, CA125, CA199, HBV or HCV infection and tumor size (P>0.05). The expression of MAGE-A3 showed correlation with the high expressions of CEA in serum (r=0.30, P=0.03), AFP in serum (r=0.26, P=0.03) and lymph node metastases (r=0.30, P=0.01).
Our findings demonstrate the cancer testis expression of CTAs genes show correlations with tumor stages and proliferation and may represent useful targets for tumor specific immunotherapy in HCC patients.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.